The Latest

  • alcohol bottles illustration
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    As alcohol-related deaths climb, new drugs could curb the urge to drink

    A drug developed by Kinnov Therapeutics halved alcohol consumption in heavy drinkers in a mid-stage study.

  • Dr. Victoria Zazulina, global head of oncology development, EMD Serono
    Image attribution tooltip
    Permission granted by EMD Serono
    Image attribution tooltip

    How EMD Serono plans to hit its lofty goals in R&D

    The company’s global heads of oncology R&D reveal how strategic partnerships are key to its launch plans following layoffs in the U.S.

  • Dr. Juan Camilo Arjona Ferreira, chief medical officer, Organon
    Image attribution tooltip
    Permission granted by Organon
    Image attribution tooltip
    Q&A // First 90 Days

    Organon’s chief medical officer wants to change how the world sees women’s health

    Dr. Juan Camilo Arjona Ferreira joined Organon in September and says the company is “like a lighthouse in women’s health” in its visibility and focus.

  • COO, chief operating officer
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    The biopharma COO’s playbook

    Connie Chang, COO at ONL Therapeutics, describes what it takes to bring a CEO’s vision to life.

  • body muscle
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Biohaven wants to muscle in on the Ozempic craze with a competing class of drugs

    Biohaven and other companies are aiming to develop meds with a different mechanism of action that trim the waistline while building lean tissue.

  • man in dark tunnel
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    ​​A startling drop in U.S. life expectancy — and how pharma could help turn the tide

    The recently observed dip was particularly acute for men, who now live an average of 5.8 fewer years than women.

  • Janet Woodcock in senate
    Image attribution tooltip
    Chip Somodevilla via Getty Images
    Image attribution tooltip

    Top FDA official Woodcock to retire early next year

    The 37-year veteran helmed the agency’s pandemic response, and was a key decision-maker in controversial calls on opioids, an Alzheimer's therapy and muscular dystrophy drugs.

  • Dr. Paul Moss, deputy head, College of Medical and Dental Sciences, Professor of Haematology, University of Birmingham
    Image attribution tooltip
    Permission granted by AstraZeneca/U. of Birmingham
    Image attribution tooltip
    Q&A

    AstraZeneca showed the pandemic isn’t over for immunocompromised patients. What’s next?

    Dr. Paul Moss, a hematology expert in the U.K., conducted a study with AstraZeneca showing the alarming extent to which immunocompromised patients are burdened with COVID-19.

  • Genomics DNA
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    The power of genomics-based healthcare remains largely untapped

    23andMe co-founder and CEO Anne Wojcicki discusses ways the industry could integrate genomics into healthcare.

  • Lindsay Pino, co-founder, chief technology officer, Talus Bio
    Image attribution tooltip
    Permission granted by Talus Bio
    Image attribution tooltip
    Biotech Spotlight

    A biotech tackles drug discovery with transcription factor know-how

    Talus Bio, which developed a platform to map transcription factors, has a lead cancer candidate in the works and consults with other industry players in the complicated biology.

  • Denise Bronner headshot
    Image attribution tooltip
    Permission granted by Johnson & Johnson Innovative Medicine
    Image attribution tooltip

    6 ways to improve clinical trial diversity — as shown by J&J

    Johnson & Johnson Innovative Medicine’s director of diversity, equity and inclusion in clinical trials shares key strategies for making DEI work.

  • A photograph of a Sarepta building in Boston, MA
    Image attribution tooltip
    Courtesy of Sarepta
    Image attribution tooltip

    Can Sarepta’s Duchenne gene therapy still deliver on its promise?

    For Sarepta — and DMD patients — there’s a lot riding on the treatment’s next steps.

  • moquito art
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Humans can’t shake the mosquito threat. Here’s what pharma has in the pipeline.

    The arsenal against the world’s deadliest creature is growing and a universal vaccine is in the works.

  • ceo pay
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    5 of the best paid biopharma CEOs

    As revenue growth remained high last year, so did biopharma CEO pay in the U.S.

  • 2023 Red Jacket header
    Image attribution tooltip

    Photo illustration: Industry Dive

    Image attribution tooltip

    The 2023 Red Jacket honorees

    This year's inductees to the PharmaVoice 100 "hall of fame" are leaders who have been at the forefront — and will stay at the forefront — of industry change.

  • Jean Jacques Bienaime headshot
    Image attribution tooltip
    Permission granted by BioMarin
    Image attribution tooltip
    Making Moves

    Does BioMarin’s CEO shuffle signal bigger changes ahead?

    With its long-time CEO on the way out, the rare disease biotech has seen an activist investor grow its stake.

  • A scale is foregrounded against the sky.
    Image attribution tooltip
    zennie via Getty Images
    Image attribution tooltip

    How pharma leaders talk about ethics in a highly criticized industry

    The maze of ethical issues in biopharma can confound even the wiliest executive. How do some leaders get by?

  • A sickle cell and normal blood cells are seen in red against a blue background in this colorized microscope image.
    Image attribution tooltip

    Janice Haney Carr/CDC/Sickle Cell Foundation of Georgia/AP

    Image attribution tooltip
    Deep Dive

    What if a CRISPR cure isn’t such an easy choice?

    A gene editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics can mute sickle cell disease’s most damaging symptoms. Yet treatment may not be as simple as its dramatic benefit makes it seem.

  • FluMist
    Image attribution tooltip
    Mario Tama / Getty via Getty Images
    Image attribution tooltip

    An at-home flu vaccine? If approved, it could open the door to more DIY options

    A new way to administer vaccines at home could help AstraZeneca reach a wider market for FluMist, the nasal influenza vaccine.

  • Sarah Boyce, CEO and president, Avidity Biosciences
    Image attribution tooltip
    Permission granted by Avidity
    Image attribution tooltip
    Biotech Spotlight

    A new delivery method muscling its way into the RNA space

    With an AOC platform targeting muscle diseases, Avidity Biosciences hopes to break open the possibilities of RNA.

  • Anne Wojcicki red carpet
    Image attribution tooltip
    Dia Dipasupil via Getty Images
    Image attribution tooltip
    Q&A

    23andMe CEO Anne Wojcicki’s vision for changing healthcare as a ‘full-fledged biotech’

    23andMe always had bigger aims than at-home genetics testing. In this in-depth interview, the company’s founder explains its foray into pharma, drug R&D, solving cold cases and more.  

  • Arthur Caplan, professor of bioethics and founding head of the Division of Medical Ethics, NYU’s Grossman School of Medicine
    Image attribution tooltip
    Permission granted by NYU
    Image attribution tooltip
    Opinion

    The thorniest questions facing pharma, according to a leading bioethicist

    Bioethics guru Arthur Caplan of NYU gives his outspoken and frank opinion on the industry’s minefield of ethical challenges.

  • Boxes of the diabetes drug Ozempic are seen on a pharmacy counter.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    The obesity drug effect: What medical device executives are saying

    Investor concerns that interest in GLP-1s will slow demand for medical devices and procedures have shaved roughly $370 billion in value from stocks across the medtech sector, according to research by Mizuho.

  • dollar sign blowing away
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    In a record year for biotech bankruptcy, here are 3 companies that went under

    A challenging funding environment and lack of partnering deals have contributed to the market's ongoing troubles.

  • Entrepreneur heeader
    Image attribution tooltip

    Photo illustration: Industry Dive; Getty Images

    Image attribution tooltip
    PharmaVoice 100

    PharmaVoice 100s: Entrepreneurs

    From biotech startups to a services agency, these entrepreneurs are hedging their bets to offer innovative approaches in patient care.